Latest News:

Nov 07, 2019

PDS Biotechnology Reports Third Quarter 2019 Financial Results and Provides Business Update

Read More

Nov 06, 2019

PDS Biotechnology Accepted for Oral Presentation at the 34th Annual Society for Immunotherapy of Cancer Annual Meeting

Read More

Oct 22, 2019

PDS Biotechnology Completes Manufacturing of Clinical Batches of PDS0101

Read More

PDS BIOTECHNOLOGY HAS MERGED WITH EDGE THERAPEUTICS

 

ABOUT PDS BIOTECHNOLOGY

PDS Biotechnology is a clinical stage immuno-oncology company with a growing pipeline of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers.

All of PDS’s products are based on the proprietary Versamune® platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.